(AAPL) Archives - Page 6 of 112 - Mad Hedge Fund Trader

Ready, Reset, Go

I had to laugh when I saw Johnson & Johnson's (JNJ) Q4 earnings hit my screen earlier this month.

Here we have Wall Street wringing its hands over a slight revenue miss, sending shares down 3.5%, while management is busy plotting its path to pharma industry dominance.

The numbers tell an interesting story.

Q4 revenues grew 5.3% (or 5.7% on an adjusted operational basis) to $22.5 billion. Wall Street got the vapors because earnings came in at $1.41 per share, well below their $2.04 consensus.

Reminds me of the time analysts completely missed Apple's (AAPL) transformation into a services company.

For the full year 2024, JNJ delivered 4.3% sales growth (5.4% operational) to $88.8 billion, with earnings per share landing at $5.79, or $9.98 adjusted after swallowing a $(0.67) hit from acquired IPR&D charges.

Not too shabby for a company in transition.

Looking into 2025, management is guiding for 2.5-3.5% operational sales growth ($90.9-91.7 billion) and adjusted operational EPS of $10.75-$10.95.

That's 8.7% growth at the midpoint, though they're careful to hedge around legal proceedings and acquisition costs.

And here's where it gets interesting.

During last week's JP Morgan Healthcare Conference, CEO Joaquin Duato was practically bouncing in his chair about their drug pipeline. Let's look at what's got him so excited.

Darzalex, their multiple myeloma superstar, raked in $11.67 billion in 2024, up 20%.

The new kid Carvykti exploded 93% higher to $963 million. Tecvayli landed $550 million in its rookie year.

Depression med Spravato jumped 56% to hit the magic $1 billion mark. Tremfya, their Stelara successor, grew 17% to $3.7 billion.

Speaking of Stelara – there's the elephant in the room.

JNJ's crown jewel is losing patent protection, already showing up in Europe with a >12% sequential decline in Q4 to $2.35 billion. Expect a 30% "haircut" this year.

But here's what Wall Street is missing: JNJ saw this coming years ago.

They just dropped $14.6 billion on Intracellular Therapies, mostly debt-funded (they can afford it with only $31.3 billion in long-term debt and $19.98 billion in cash).

This brings them Caplyta, an antipsychotic med with blockbuster potential that's already approved for schizophrenia and bipolar disorders.

The medical device business isn't sitting still either.

Q4 worldwide revenues jumped 6.7% year-on-year. While Surgery was flat at $2.5 billion and Orthopedics grew a modest 2.5% to $2.32 billion, Vision popped 9% to $1.3 billion.

But the real story? Cardiovascular surged 24% to $2.1 billion. Those Shockwave and Abiomed acquisitions are looking pretty smart right about now.

For the year, MedTech grew 4% to $31.56 billion. Operating margins slipped a bit – Innovative Medicines down from 42% to 39.4%, MedTech from 23.7% to 21.6%.

Late-stage pipeline products nearing approval should ease R&D expenses in 2025, just as JNJ gears up for its next growth phase.

The foundation looks rock solid - $19.98 billion in cash, $31.3 billion in long-term debt, 2025 adjusted EPS guidance of $10.75-$10.95, and that reliable $1.24 quarterly dividend.

But forget the current numbers - the real money's in what's coming next.

Here's what the market is missing: JNJ is promising 5-7% compound annual growth between 2025-2030, with ten drugs hitting $5+ billion in annual sales by decade's end.

Sound ambitious? Maybe. But they've got the pipeline to back it up – from immunology stars nipocalimab and icotrokinra to neuroscience contenders seltorexant and aticaprant, plus oncology plays like TAR-200 for bladder cancer.

I've seen this movie before with AbbVie (ABBV), which navigated the loss of $20+ billion Humira without missing a beat.

And JNJ looks even better positioned - their pharma division is targeting $58 billion in 2024 revenues, which would make them the biggest player in Big Pharma, ahead of Pfizer (PFE), AbbVie (ABBV), Roche (RHHBY), AstraZeneca (AZN), Sanofi (SNY) and Novartis (NVS).

The only real wildcard? That pesky talc litigation.

JNJ's latest move – spinning the lawsuits into Red River Talc LLC and filing for bankruptcy – could cap the damage at $8.5 billion. They claim 75% of claimants are on board, with a court ruling expected this month.

So, what's my take? I think JNJ's 2025 will be a "reset" year, especially the first half. But just like buying straw hats in winter, there might be an opportunity here for patient investors. Management says the back half will be stronger, setting up 2026 for what could be a very interesting guidance call.

While the market frets about Stelara's patent cliff, smart money is quietly building positions. That's why I'm maintaining my stand to buy the dip.

After all, sometimes the best trades are the ones that make you a bit uncomfortable at first. And if you're worried about patent cliffs, just ask any AbbVie shareholder how that worked out for them.

January 23, 2025

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
January 23, 2025
Fiat Lux

Featured Trade:

(THE HARD TRUTH ABOUT THIS BIOTECH'S PIPELINE THAT WALL STREET DOESN'T GET)

(MRK), (AMGN), (AAPL)

The Hard Truth About This Biotech's Pipeline That Wall Street Doesn't Get

Biotech Letter

Earlier this month, while reviewing my biotech holdings during a layover at Chicago O'Hare, I got an interesting call from a long-time reader.

He was panicking about Merck (MRK) after seeing it trading near its 52-week lows, convinced the pharmaceutical giant was headed for trouble.

"Have you seen what Medicare negotiations did to Januvia?" he asked, referencing the 79% price reduction. "And Keytruda's patent expires in 2028!"

Here's the hard truth about this biotech's pipeline that Wall Street doesn't get: while everyone's fixated on Keytruda's patent cliff, Merck has quietly tripled their late-stage pipeline in just over three years.

We're talking more than 20 unique assets in late-stage development, plus another 50 in early stages.

The last time I saw this kind of pipeline expansion was during the early days of Amgen (AMGN), which turned out pretty well for investors who saw past the obvious.

Actually, Merck's current "crisis" also reminds me of the time I bought Apple (AAPL) right after Steve Jobs announced the iPhone. Everyone worried about the risk, while I saw the opportunity.

Merck just posted Q3 2024 numbers that would make most CEOs envious: revenue up 7% year-over-year to $16.7 billion.

Keytruda, their cancer blockbuster, grew 21% to $7.4 billion. Even their Animal Health division jumped 11%. These aren't the numbers of a company in trouble.

Speaking of investors, they've enjoyed a 126% total return over the past decade with Merck, despite more ups and downs than my last flight through turbulence.

The company's 5-year average Return on Equity sits at 25% (recently climbing to 28%), with Return on Invested Capital steady at 20%.

With a Weighted Average Cost of Capital around 8%, there's plenty of room for growth.

Yesterday, I was discussing these numbers with a former FDA commissioner (who shall remain nameless) over coffee.

He pointed out something fascinating: Merck's R&D spending is increasing alongside revenue growth. That's like a tech company doubling down on product development – exactly what you want to see in pharma.

For dividend hunters (and I know many of you are), Merck offers a 3.3% yield with a 7% five-year dividend growth rate.

The payout looks sustainable too, consuming 68% of earnings and 55% of free cash flow. It's not going to make you quit your day job, but it's better than the 1.4% you'll get from the S&P 500.

Looking at valuation, Merck trades at a P/E of 20.5, below its historical average of 22.3.

My own growth projections suggest a 13% annual rate going forward. Optimistic? Perhaps. But with their robust pipeline and near-term analyst projections, I've seen crazier things work out.

The company just announced a $15 billion share repurchase program, including plans to spend $7.5 billion over the next 12 months. When management puts that kind of money where their mouth is, I tend to pay attention.

Yes, Keytruda's patent cliff in 2028 is real. But so is Merck's late-stage pipeline of antibody-drug conjugates (ADCs) – think smart missiles in the war against cancer.

And unlike some biotechs, Merck has the financial muscle to weather any storm, with decreasing net debt and a solid cash position.

Remember what I always say about buying straw hats in winter? Merck right now is like finding a premium pharma stock in the discount bin.

Just like my friend who panicked and sold everything after the November 8 election (and missed the subsequent rally), sometimes the best opportunities come disguised as problems.

As for me, I'm looking at Merck as a potential long-term hold. The company's fundamentals remind me of other great turnaround stories I've traded successfully over the years.

With the healthcare sector currently out of favor and Merck trading near its 52-week lows, this might be one of those moments we look back on and wish we'd bought more.

And speaking of patents, maybe I should patent my strategy: “Buy great companies when everyone else is afraid.” Though I suspect Warren Buffett already beat me to that one.

January 13, 2025

Tech Letter

Mad Hedge Technology Letter
January 13, 2025
Fiat Lux

Featured Trade:

(APPLE DROPS THE BALL)
(AAPL), (SAMSUNG), (CHINA)

Apple Drops The Ball

Tech Letter

Not only is Apple losing its edge, but they are failing miserably against the Chinese.

China, with its state-supported behemoths, is the bully on the playground and Apple can’t too diddlysquat.

Apple has been selling the same product for the past 13 years and the last iterations have been underwhelming, to say the least.

People don’t want to upgrade forcing them to elongate the refresh cycle.

It’s now so bad that Apple even ceded a 5% market share in the final quarter last year to Chinese competition.

Apple is also very late in integrating AI features signaling that Apple’s software game is behind the times and mediocre at best.

Apple risks falling behind quickly and the Chinese have really nailed the consumer tech and muscled into this industry.

They are poised to dominate EVs and smartphones and other value-added tech in the upcoming years.

They plan to seize the moment and squeeze American companies out of the way for good.

Samsung also has been going through a disastrous downcycle after their Android flagship phone peaked a few years ago.

This new trajectory is a slippery slope and if Apple goes on the cost-cutting path, there will be little talent left to innovate out of this problem.

The iPhone slipped a point to 18% worldwide market share in 2024.

Apple marked a 2% sales decline for the full year, at a time when the wider market grew 4% globally.

China’s smartphone makers are all developing their own in-house AI tools and agents, including services that can perform tasks on a user’s behalf.

Samsung also gave up its share to faster-growing Android device makers from China, led by Xiaomi and Vivo. Apple marked a 2% sales decline for the full year.

The situation paints a picture of the non-Chinese smartphone markets in a world of hurt.

I believe that Apple and Samsung have nobody to blame, but themselves as those years of forced technological know-how transfer are coming back to bite them where it hurts.

My friends’ kids have these new Chinese smartphones and I can tell you that I was surprised about how good they perform.

They are run on Android, which is very different from IoS, but they are premium.

German car companies are also feeling this bitter pill as Chinese companies have taken their own technology and implemented it in a more affordable way.

In aggregate, this latest news is a bad omen for Apple’s earnings season.

They are barely jumping over a lower bar and that will keep happening until something major is revamped in the product lineup.

I believe any steep sell-off would be a nice opportunity to execute a short-term trade, but those years of buying and holding Apple until eternity are gone.

Readers must really nitpick what this company is doing because management presides over a dull model and their China business is falling apart as we speak all while they helped the local Chinese competition over many years take market share with forced technological transfers.

Not a good look and things could get worse as we move deeper into the year.

New Video Update on How to Execute a Vertical Bull Call Debit Spread

Diary, Newsletter

I have just updated the training video for Vertical Bull Call Debit Spreads that goes out with every trade alert. With a market meltdown forecast for the new year, some great entry points for these will be setting up.

Since then, we have learned a lot from customer questions. The nature of the options markets has also changed. So, the new video extends to 27:43 minutes. To watch it in its entirety, please click here.

I recommend watching it on full screen so you can read all the numbers on my options trading platform.

We have recently had a large influx of new subscribers.

I have no idea why. Maybe it’s my sterling personality and rapier-like wit.

Most investors make the mistake of investing in positions that have only a 50/50 chance of success, or less. They’d do better with a coin toss.

The most experienced hedge fund traders find positions that have a 99% chance of success and then leverage up on those trades. Stop out of the losers quickly and you have an approach that will make you well into double digits, year in and year out, whether markets go up, down, or sideways.

Bring on the Vertical Bull Call Debit Spread.

This is a matched pair of positions in the options market that will be profitable when the underlying security goes up, sideways, or down in price over a defined limited period of time.

It is the perfect position to have onboard during markets that have declining or low volatility, much like we have experienced for most of the last several years, and will almost certainly see again.

I have strapped on quite a few of these babies across many asset classes this year, and they are a major reason why I am up so much last year.

To understand this trade, I will use the example of Apple trade, which most people own and know well.

On October 8, 2018, I sent out a Trade Alert by text message and email that said the following. Please note these are pre-split prices.

BUY the Apple (AAPL) November 2018 $180-$190 in-the-money vertical BULL CALL spread at $8.80 or best.

At the time, Apple shares were trading at $216.17. To accomplish this, they had to execute the following trades:

Buy 11 November 2018 (AAPL) $180 calls at….………$38.00

Sell short 11 November 2018 (AAPL) $190 calls at….$29.20

Net Cost:…………………….………..………….…..................$8.80

A screenshot of my own trading platform is below:

This gets traders into the position at $8.80, which costs them $9,680 ($8.80 per option X 100 shares per option X 11 contracts).

The vertical part of the description of this trade refers to the fact that both options have the same underlying security (AAPL), the same expiration date (November 16, 2018), and only different strike prices ($180 and $190).

The maximum potential profit can be calculated as follows:

+$190.00 Upper strike price
-$180.00 Lower strike price
+$10.00 Maximum Potential Profit

Another way of explaining this is that the call spread you bought for $8.80 is worth $10.00 at expiration on November 16, giving you a total return of 13.63% in 27 trading days. Not bad!

The great thing about these positions is that your risk is defined. You can’t lose any more than the $9,680 you put up.

If Apple goes bankrupt, we get a flash crash, or suffer another 9/11-type event, you will never get a margin call from your broker in the middle of the night asking for more money. This is why hedge funds like vertical bull call spreads so much.

As long as Apple traded at or above $190 on the November 16 expiration date, you will make a profit on this trade.

As it turns out, my take on Apple shares proved dead-on, and the shares rose to $222.22, or a healthy $32 above my upper strike.

The total profit on the trade came to:

($10.00 expiration - $8.80 cost) = $1.20

($1.20 profit X 100 shares per contract X 11 contracts) = $1,320.

To summarize all of this, you buy low and sell high. Everyone talks about it but very few actually do it.

Occasionally, Vertical Bull Call Spreads don’t work and the wheels fall off. As hard as it may be to believe, I am not infallible.

So if I’m wrong and I tell you to buy a vertical bull call spread, and the shares fall not a little, but a LOT, you will lose money. In those rare cases when that happens, I’ll shoot out a Trade Alert to you with stop-loss instructions before the damage gets out of control.

I start looking at a stop loss when the deficit hit 10% of the size of the position or 1% of the total capital in my trading account.

To watch the video edition of How to Execute a Vertical Bull Call Spread complete with more detailed instructions on how to execute the position with your own online platform, please click here.

Good luck and good trading.

Vertical Bull Call Spreads Are the Way to Go in a flat to Rising Market

December 31, 2024

Biotech Letter

Mad Hedge Biotech and Healthcare Letter
December 31, 2024
Fiat Lux

Featured Trade:

(SOMETIMES WALL STREET GETS IT WRONG)

(BMY), (AAPL), (MRK)

Sometimes Wall Street Gets It Wrong

Biotech Letter

Sitting in my stateroom aboard the Coral Princess, about 200 miles off Mexico's west coast, I found myself chuckling at the market's reaction to Bristol-Myers Squibb’s (BMY) latest developments. Sometimes Wall Street reminds me of my old physics professor - brilliant but occasionally missing the forest for the quantum trees.

Here's what caught my attention: BMY's stock has outperformed the broader market by +15% since July, yet still trades at a measly 7.91x forward P/E while its sector peers strut around at 20.53x. It's like finding a Ferrari in a used car lot, priced like a Corolla.

The cynics, of course, point to the patent cliff. "What about Eliquis in 2026? Opdivo in 2028?" they ask, wringing their hands. But that's exactly where it gets interesting.

Just earlier this month, BMY announced FDA approval for Opdivo Qvantig - their new subcutaneous version that cuts treatment time from 30 minutes to 5 minutes. If you've ever spent time in cancer treatment centers like I have, you know those 25 minutes make a world of difference.

BMY's commercial team expects this version to capture 75% of Opdivo's business, with 30-40% of patients switching from IV. That's not just convenience - it's strategic patent life extension.

Speaking of strategy, let's talk about their growth portfolio, which has quietly expanded 20% year-over-year and now represents 48.7% of their business.

Remember when Apple (AAPL) transformed from computers to mobile devices? BMY is pulling a similar pivot, just without the flashy keynotes.

Take their $14 billion Karuna acquisition. Their newly approved schizophrenia treatment, Cobenfy, targets a market projected to hit $15.23 billion by 2034. The timing here is masterful - monetization starts in early 2025, well before the patent cliffs hit.

Meanwhile, they're cleaning up their balance sheet faster than a neat freak with a new vacuum. They've already slashed $4.31 billion in debt this year, with plans to cut $10 billion by 2026.

Their free cash flow has grown to $13.8B, up 18.1% sequentially. At this rate, they'll have plenty of dry powder for more strategic moves.

But here's what really makes me scratch my head: while everyone's fixated on the patent cliff, BMY has quietly added 8 new oncology registrational trials in the past year. Their oncology trio - Opdivo, Yervoy, and Opdualag - is growing at 7.6% year-over-year.

Sure, Merck's (MRK) Keytruda is the 800-pound gorilla with $25 billion in sales, but BMY's playing a different game - diversification with shots on goal across multiple therapeutic areas.

Now, I'm not suggesting you back up the truck tomorrow morning. The stock might see some pressure after the January 3, 2025 ex-dividend date, possibly testing support at $51 or even $48. But with a 4.45% dividend yield and a valuation at half its historical average, patient investors might find this an interesting entry point.

Speaking of timing - Wall Street's greatest fortunes were made by investors who saw value where others saw problems. Right now, most analysts are staring at BMY's patent cliff like deer in headlights.

Meanwhile, I'm seeing a company with a 4.45% dividend yield, a growth portfolio expanding at 20% annually, and a valuation that's practically begging to double.

As I wrap this up from somewhere off the Mexican coast (where I'm supposedly on vacation but can't help analyzing stocks between rounds of Monopoly), I'm reminded of something I learned in my decades of trading: The crowd is usually looking through the wrong end of the telescope.

While they're zoomed in on 2026's patent expirations, they're missing the transformation happening right now in front of their eyes.

Maybe that's why I've averaged +50% returns for over a decade - I tend to look where others don't. BMY just might be one of those opportunities that makes next year's Christmas gift to my subscribers an even bigger winner than this year's +75.25% return.

Now, if you'll excuse me, my banjo needs tuning, and I have a Monopoly empire to build. But remember - in both board games and markets, the best players are always thinking three moves ahead. BMY's management certainly is.